Early response to neoadjuvant chemotherapy can help predict long-term survival in patients with cervical cancer.
Ontology highlight
ABSTRACT: It is still controversial whether cervical cancer patients with clinical responses after neoadjuvant chemotherapy (NACT) have a better long-term survival or not. This study was designed to investigate the effect of the clinical response on the disease-free survival (DFS) of cervical cancer patients undergoing NACT. A total of 853 patients from a retrospective study were used to evaluate whether the clinical response was an indicator for the long-term response, and 493 patients from a prospective cohort study were used for further evaluation. The survival difference was detected by log-rank test, univariate and multivariate Cox regression and a pooled analysis. The log-rank test revealed that compared with non-responders, the DFS of responders was significantly higher in the retrospective d
SUBMITTER: Li X
PROVIDER: S-EPMC5350004 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA